Core Insights - LifeMD, Inc. has expanded its pharmacy capabilities to include advanced non-sterile compounding for oral and topical medications, enhancing its vertically integrated platform to better meet patient needs and improve efficiency [1][3] - The commercial pharmacy, launched in August 2024, can now process up to 5,000 prescriptions daily and formulate customized medications, including allergen-free and combination products [2] - LifeMD's compounding pharmacy operates under the FDA's 503A designation, ensuring adherence to strict quality and safety standards, and is currently licensed in 13 states with plans to expand to all 50 states within the next year [3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory access, and pharmacy services across more than 200 conditions, including men's and women's health, weight management, and hormone therapy [4] - The company utilizes a proprietary digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care [4]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook, leading to a significant drop in share price [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs [3]. - Following the revelation of the true facts, LifeMD's shares plummeted by 44%, equating to a decrease of $5.31 per share in a single trading session [3].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding LifeMD's competitive position and financial guidance for 2025 [1]. - It is alleged that the defendants did not properly account for rising customer acquisition costs in LifeMD's RexMD segment and related to obesity treatment drugs [1]. - The statements made by the defendants about LifeMD's business operations and prospects were claimed to be materially false and misleading [1]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [2]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects during the period from May 7, 2025, to August 5, 2025 [1][2]. Group 1: Allegations and Misconduct - The lawsuit claims that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The defendants' statements regarding LifeMD's business operations and prospects were allegedly materially false and misleading, lacking a reasonable basis throughout the relevant period [2]. Group 2: Financial Impact - Following the announcement of its second quarter 2025 results on August 5, 2025, which indicated temporary challenges in the RexMD business, LifeMD revised its full-year 2025 revenue and adjusted EBITDA guidance, leading to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Group 3: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by October 27, 2025 [4]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required to be eligible for recovery [4]. Group 4: Company Background - Robbins LLP, the law firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=166931&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during a specified class period [1]. Summary by Sections Allegations - The complaint alleges that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management overstated the company's competitive position [1]. - It is claimed that the company recklessly raised its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of LFMD during the specified timeframe are encouraged to register for the class action by October 25, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against LifeMD, Inc. on behalf of investors who purchased the company's securities between May 7, 2025, and August 5, 2025, alleging misrepresentations regarding the company's competitive position [1][2]. Group 1 - The lawsuit is initiated by a shareholder representing a class of investors who acquired LifeMD securities during the specified period [1]. - The complaint claims that the defendants made false statements about LifeMD's competitive standing in the market [2]. - Investors interested in participating in the lawsuit must file papers by October 27, 2025, to serve as lead plaintiff, although participation in any recovery does not require this role [3]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's second-quarter results announced on August 5, 2025, missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and issues with patient refunds [4]. - Following the earnings call, LifeMD's stock price dropped by over 44% the next day, reflecting investor reaction to the disclosed challenges [4]. Investigation and Recovery Opportunities - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims against LifeMD, focusing on whether the company was aware of but failed to disclose key operational issues [6]. - The lawsuit provides an opportunity for investors who suffered significant losses during the specified period to seek recovery of damages [5].

Core Viewpoint - A class action lawsuit has been initiated against LifeMD, Inc. on behalf of investors who purchased the company's securities between May 7, 2025, and August 5, 2025, seeking to recover losses incurred during this period [1][3]. Summary by Sections Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance for 2025, failing to account for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. Investor Information - Investors who suffered losses have until October 27, 2025, to seek appointment as lead plaintiff and can visit the provided link for more information on eligibility for potential recovery [2]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, representing both individual and institutional investors [4].

Core Viewpoint - LifeMD, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between May 7, 2025, and August 5, 2025, impacting investors adversely [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding LifeMD's competitive position and recklessly raised the company's 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The allegations suggest that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant times [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].